TrialBlood cancer journal2025

Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Eva Domingo-Domènech et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.